238-101-9

应用筛选条件

关键词:'238-101-9'

显示 1-1 共 1 条结果关于 "238-101-9" 范围论文

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.

K Rajender Reddy et al.

The Lancet. Infectious diseases, 15(1), 27-35 (2014-12-09)

We did a phase 3 study in previous non-responders with chronic hepatitis C virus (HCV) genotype 1 infection and compensated liver disease that related to the standard of care for these patients at the time this study was initiated. We

1/1